Healthcare

• The company raised its full-year 2026 organic sales guidance to 10.0%–10.5%, up from 9.0%–10.0%, and reaffirmed Adjusted EBITDA guidance of $3.3–$3.4 billion

• Phase 3 IZAR-1 trial in psoriatic arthritis met all clinical endpoints at Week 16 for sonelokimab 60 mg with induction, showing a 42.1% ACR50 response rate

• NewAmsterdam initiated the SPINOZA Phase 2b trial evaluating obicetrapib in preclinical Alzheimer's disease.

• Phase 1 trial of NLRP3 inhibitor ACI-19764 showed positive interim safety and tolerability results in healthy volunteers

• Phase 1 clinical trial expanded from three to nine active sites, with enrollment expected to reach six to ten patients per month in Q4 2026

• Operating profit came in at $53.3 million on aGAAPbasis and $86.5 million on a non-GAAP basis for the quarter.

• The company completed a $4.0 million registered direct offering in September 2026, expected to fund operations through mid-first quarter 2027.